mdRNA
announced today updates on results in mice for their liposomally delivered RNAi Therapeutics candidates for solid cancers. They also said to have entered into an "early collaborative effort with a major international pharmaceutical company". While not negative news for sure, both types of news items would appear to make the 75% run-up in shares this morning to be an over-reaction, especially given the one-month window it has to find additional funding. I will therefore take a trading profit at $1.71, and possibly look to re-enter the stock, maybe after an opportunistic financing following today's announcement.
Disclaimer: Investments in RNAi Therapeutics are highly risky and not suited for most people.The purpose of the blog and model portfolio is to convey a sense of the dynamics in the field and is NOT an endorsement for making related investments. I also have financial interests in some of the companies included in the portfolio. I do not, however, have short positions in any of those.
Guru
ReplyDeleteLook back to October and the MRNA press releases..This is the same rodent data with a different spin..
What I wanted to see was the primate data and it was not even in the latest release.
Saying they are collaborating again?.Why would a shareholder not expect them to be doing that 100% of the time!
I felt the ALNY news last week was interesting and it got no press.
Excellent call Dirk!
ReplyDeleteThey got their financing then.
The terms could have been worse.